TerraPower Isotopes is set to develop a new $450 million manufacturing site in Bellwether District, Philadelphia. The move comes after a nationwide search as it settles for Philadelphia as its second manufacturing site. Gov. Josh Shapiro’s office announced the deal, saying TerraPower will develop a custom-built, 250,000-square foot facility. Furthermore, he noted the facility will manufacture actinium-225.

It is a radioisotope derived from weapons-grade uranium and used in the development of a drug that destroys cancerous tissue with minimal damage to healthy cells. The state said it landed the facility over 350 other possible sites with the help of $10 million in state grants. The company will also qualify for tax benefits as the Bellwether District is in a Keystone Opportunity Zone. According to the governor’s office, it will create 225 full-time jobs over the next three years. The neighboring state of Ohio is also advancing cancer research as it commences construction on a $226 million Comprehensive Outpatient Cancer Center at its David P. Blom Administrative Campus at 3430 OhioHealth Parkway in Columbus, Ohio

Outlook on the TerraPower Isotopes Manufacturing Site in Bellwether

The TerraPower Isotopes new manufacturing site in Bellwether is one that brings along tremendous advantages for Philadelphia. In his earlier X post, Governor Shapiro noted that, “we have secured another MAJOR WIN in the life sciences,” highlighting the significance of the project. Similar remarks were also reiterated by Philadelphia Mayer Cherrelle L. Parker. “TerraPower Isotopes’ decision to locate its flagship East Coast facility at The Bellwether District is a major win for Philadelphia,” he noted.

“This investment will create hundreds of good-paying jobs, strengthen our advanced manufacturing and life sciences sectors, and also expand economic opportunity. Exciting things are coming to South Philly, and we are just getting started. This means more economic mobility for Philadelphians.” The firm’s development of an East Coast manufacturing facility, along with expanding capacity in its existing Everett, Washington facility, will increase production capacity 20-fold.

Moreover, it will position the company as the premier global distributor of actinium-225. This new cGMP Bellwether Laboratory is expected to further expand actinium-225 supply reliability. Furthermore, it will increase production levels to support global drug needs for the next decade.

Project Factsheet:

• Name: TerraPower Isotopes Manufacturing Facility
• Developer: TerraPower Isotopes
• Location: Bellwether District, Philadelphia, Pennsylvania, USA
• Type: Radioisotope Manufacturing Facility
• Facility Size: 250,000 sq ft
• Investment Value: $450 million
• Primary Product: Actinium-225 (medical radioisotope for cancer treatment)
• Job Creation: 225 full-time jobs (within 3 years)

Government Support:

• Josh Shapiro (Governor of Pennsylvania)
• $10 million in state grants

Local Authority:

• Cherelle L. Parker (Mayor of Philadelphia)

Incentives:

• Keystone Opportunity Zone tax benefits

Site Selection: Chosen over 350+ locations nationwide

Existing Facility Expansion:

• Everett, Washington (capacity expansion alongside new site)

Production Impact:

• 20× increase in actinium-225 production capacity
• It also strengthens global supply for cancer treatment drugs

Facility Standard: cGMP (current Good Manufacturing Practice) laboratory

Status: Announced / Pre-construction

Key Significance:

• Positions TerraPower as a leading global supplier of actinium-225
• Also expands reliable supply of critical cancer treatment materials.